ArticleFrontiers in immunology2022
Fighting MDR-
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- Inhibition of prolyl-tRNA synthetase and efflux pumps as a dual-targeting strategy against multidrug-resistant bacteria.Journal of enzyme inhibition and medicinal chemistry · 2026Article
- An overview of innate cellular immune responses against hypervirulentEmerging microbes & infections · 2026Review
- Genomic characterization of an ESBL-producingMicrobiology spectrum · 2026Article
- Global Genomic Analysis of Bovine-AssociatedBiology · 2026Article
- Camellia sinensis-synthesized silver nanoparticles and meropenem combination against extensively drug-resistant Klebsiella pneumoniae.Scientific reports · 2026Article
- Host-directed therapeutics against antimicrobial-resistant bacterial infections: emerging roles of multi-omics and systems biology.Frontiers in pharmacology · 2026Review
- Identification and preclinical efficacy evaluation of two lytic bacteriophages targeting highly virulent and multidrug-resistant Klebsiella pneumoniae.Annals of clinical microbiology and antimicrobials · 2025Article
- A TAT Peptide-Functionalized Liposome Delivery Phage System (TAT-Lip@PHM) for an Enhanced Eradication of Intracellular MRSA.Pharmaceutics · 2025Article
- The first report of antibiotic resistance and virulence factor profiles in multidrug-resistant clinical isolates of Klebsiella pneumoniae from Pontianak, Indonesia.Osong public health and research perspectives · 2025Article
- Molecular Characterization of PresumptivePathogens (Basel, Switzerland) · 2025Article
- Snapshot of Defense Systems in Multidrug ResistantmicroPublication biology · 2025Article
- Isoferulic acid facilitates effective clearance of hypervirulent Klebsiella pneumoniae through targeting capsule.PLoS pathogens · 2025Article
- Article
- Risk factors associated with multidrug-resistant Klebsiella pneumoniae infections: a multicenter observational study in Lebanese hospitals.BMC public health · 2024Observational
- Effect of biogenic bismuth nanoparticle on the expression of New Delhi metallo-β-lactamase (NDM) gene in Multidrug-ResistantHeliyon · 2024Article
- Next generation antibiotic combinations to combat pan-drug resistant Klebsiella pneumoniae.Scientific reports · 2024Article
- Factors Associated with Extended-Spectrum β-Lactamases and Carbapenem-ResistantPathogens (Basel, Switzerland) · 2023Article
- Application of Bacteriophages for Human Health: An Old Approach against Contemporary "Bad Bugs".Microorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.